Insider Trading Alert - OPK, LVLT And LRCX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, April 4, 2014, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1.09 to $204,292,816.11.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 28,000 shares at $9.45 on April 4, 2014. Following this transaction, the CEO & Chairman owned 139.9 million shares meaning that the stake was reduced by 0.02% with the 28,000-share transaction.

The shares most recently traded at $9.33, down $0.12, or 1.33% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.0 million shares per day over the past 30 days. Opko Health has a market cap of $3.9 billion and is part of the health care sector and health services industry. Shares are up 8.89% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 4 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Level 3 Communications (LVLT) - FREE Research Report

Clemins Archie who is Director at Level 3 Communications sold 1,000 shares at $39.60 on April 4, 2014. Following this transaction, the Director owned 37,099 shares meaning that the stake was reduced by 2.62% with the 1,000-share transaction.

The shares most recently traded at $38.34, down $1.26, or 3.3% since the insider transaction. Historical insider transactions for Level 3 Communications go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 29,000
  • 24-Week # shares sold: 167,868

The average volume for Level 3 Communications has been 1.8 million shares per day over the past 30 days. Level 3 Communications has a market cap of $9.5 billion and is part of the technology sector and telecommunications industry. Shares are up 16.01% year-to-date as of the close of trading on Friday.

Level 3 Communications, Inc., together with its subsidiaries, operates as a facilities-based provider of a range of integrated communications services primarily in North America, Latin America, Europe, the Middle East, and Africa. Currently there are 5 analysts that rate Level 3 Communications a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LVLT - FREE

TheStreet Quant Ratings rates Level 3 Communications as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow. Get the full Level 3 Communications Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Lam Research Corporation (LRCX) - FREE Research Report

Anstice Martin B who is President and CEO at Lam Research Corporation sold 13,350 shares at $57.90 on April 4, 2014. Following this transaction, the President and CEO owned 150,246 shares meaning that the stake was reduced by 8.16% with the 13,350-share transaction.

Bettinger Douglas R who is EVP, Chief Financial Officer at Lam Research Corporation sold 7,360 shares at $58.90 on April 4, 2014. Following this transaction, the EVP, Chief Financial Officer owned 41,200 shares meaning that the stake was reduced by 15.16% with the 7,360-share transaction.

Heckart Christine who is Director at Lam Research Corporation sold 383 shares at $55.76 on April 4, 2014. Following this transaction, the Director owned 14,527 shares meaning that the stake was reduced by 2.57% with the 383-share transaction.

The shares most recently traded at $55.86, up $0.10, or 0.18% since the insider transaction. Historical insider transactions for Lam Research Corporation go as follows:

  • 4-Week # shares sold: 56,008
  • 12-Week # shares sold: 108,774
  • 24-Week # shares sold: 121,773

The average volume for Lam Research Corporation has been 2.3 million shares per day over the past 30 days. Lam Research Corporation has a market cap of $9.4 billion and is part of the technology sector and electronics industry. Shares are up 2.85% year-to-date as of the close of trading on Friday.

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers plasma etch products that remove materials from the wafer to create the features and patterns of a device. The company has a P/E ratio of 27.7. Currently there are 13 analysts that rate Lam Research Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LRCX - FREE

TheStreet Quant Ratings rates Lam Research Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Lam Research Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

4 Stocks Making Important Moves Wednesday

4 Stocks Making Important Moves Wednesday

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook's Investors Have a Big Day Ahead

Facebook's Investors Have a Big Day Ahead